Novocure vs Zhonghong Pulin Medical Products: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Novocure Ltd (NVCR)

Q3 202618 Jun – 24 Jul 2026

▲2▼2

TRIDENT flop then pancreatic CE Mark and raised guidance lift Novocure

TRIDENT trial fails primary endpoint Novocure's Phase 3 TRIDENT trial missed its main goal: starting Tumor Treating Fields earlier did not clearly extend overall survival in newly diagnosed glioblastoma. The stock fell about 20% as hopes for a broader label in this cancer faded.
This is the period's biggest negative event and explains the initial sharp drop.
Securities fraud investigation after TRIDENT Law firm Pomerantz is investigating Novocure for possible securities fraud tied to the TRIDENT miss. Such probes can bring legal costs, distract management, and keep some investors cautious, adding pressure on the shares.
It is a new legal overhang directly linked to the trial failure.
Optune Pax wins CE Mark for pancreatic cancer Novocure's Optune Pax received European CE Mark approval for locally advanced pancreatic cancer, backed by the PANOVA-3 trial showing longer survival and delayed pain. Launch starts in Germany, opening a new market and revenue stream.
This is a fresh regulatory win that expands the addressable market beyond brain cancer.
Q2 revenue beat and raised 2026 guidance Second-quarter revenue rose 16% to $183.6 million, and Novocure raised full-year 2026 revenue guidance to $710–$725 million while projecting positive adjusted EBITDA. The stock hit a 52-week high as investors grew more confident in the core business.
This is the main positive catalyst that reversed the earlier decline and drove the new high.

July 202618 Jun – 24 Jul 2026

▲2▼2

TRIDENT flop then pancreatic CE Mark and raised guidance lift Novocure

TRIDENT trial fails primary endpoint Novocure's Phase 3 TRIDENT trial missed its main goal: starting Tumor Treating Fields earlier did not clearly extend overall survival in newly diagnosed glioblastoma. The stock fell about 20% as hopes for a broader label in this cancer faded.
This is the period's biggest negative event and explains the initial sharp drop.
Securities fraud investigation after TRIDENT Law firm Pomerantz is investigating Novocure for possible securities fraud tied to the TRIDENT miss. Such probes can bring legal costs, distract management, and keep some investors cautious, adding pressure on the shares.
It is a new legal overhang directly linked to the trial failure.
Optune Pax wins CE Mark for pancreatic cancer Novocure's Optune Pax received European CE Mark approval for locally advanced pancreatic cancer, backed by the PANOVA-3 trial showing longer survival and delayed pain. Launch starts in Germany, opening a new market and revenue stream.
This is a fresh regulatory win that expands the addressable market beyond brain cancer.
Q2 revenue beat and raised 2026 guidance Second-quarter revenue rose 16% to $183.6 million, and Novocure raised full-year 2026 revenue guidance to $710–$725 million while projecting positive adjusted EBITDA. The stock hit a 52-week high as investors grew more confident in the core business.
This is the main positive catalyst that reversed the earlier decline and drove the new high.

Latest18 Jun – 24 Jul 2026

▲2▼2

TRIDENT flop then pancreatic CE Mark and raised guidance lift Novocure

TRIDENT trial fails primary endpoint Novocure's Phase 3 TRIDENT trial missed its main goal: starting Tumor Treating Fields earlier did not clearly extend overall survival in newly diagnosed glioblastoma. The stock fell about 20% as hopes for a broader label in this cancer faded.
This is the period's biggest negative event and explains the initial sharp drop.
Securities fraud investigation after TRIDENT Law firm Pomerantz is investigating Novocure for possible securities fraud tied to the TRIDENT miss. Such probes can bring legal costs, distract management, and keep some investors cautious, adding pressure on the shares.
It is a new legal overhang directly linked to the trial failure.
Optune Pax wins CE Mark for pancreatic cancer Novocure's Optune Pax received European CE Mark approval for locally advanced pancreatic cancer, backed by the PANOVA-3 trial showing longer survival and delayed pain. Launch starts in Germany, opening a new market and revenue stream.
This is a fresh regulatory win that expands the addressable market beyond brain cancer.
Q2 revenue beat and raised 2026 guidance Second-quarter revenue rose 16% to $183.6 million, and Novocure raised full-year 2026 revenue guidance to $710–$725 million while projecting positive adjusted EBITDA. The stock hit a 52-week high as investors grew more confident in the core business.
This is the main positive catalyst that reversed the earlier decline and drove the new high.

Zhonghong Pulin Medical Products Co. Ltd. (300981.CS)

Q3 202628 Jul – 26 Aug 2026

▲3▼1

Glove Price Surge Drives Zhonghong Medical Profit Explosion

First-Half Profit Forecast Surges Over 23-Fold Zhonghong Medical expects first-half 2026 net profit of 140–210 million yuan, up 2,338%–3,557% year-on-year, driven by higher selling prices for health protection gloves and improved cost control. This signals a strong turnaround and boosts investor confidence, pushing the stock price up.
This is the core new event that directly explains the profit surge and its cause.
Actual First-Half Net Profit Jumps 26-Fold The semi-annual report confirmed net profit of 159 million yuan, up 2,662% year-on-year, with second-quarter profit alone at 154 million yuan. Revenue rose 19.46% to 1.478 billion yuan. This concrete result validates the earlier forecast and reinforces the positive price trend.
It provides the actual financial outcome, confirming the earlier forecast and strengthening the investment case.
Stock Price Rises Over 50% Since July As of August 25, the share price stood at 14.77 yuan, up more than 50% since July, with a market value of 6.3 billion yuan. This reflects the market's positive reaction to the profit surge and improving fundamentals.
It shows the market's cumulative response to the profit news, indicating sustained upward momentum.
Large Foreign Exchange Loss from Yuan-Dollar Swings The company incurred a large exchange loss due to fluctuations in the yuan against the US dollar. Excluding this, operating performance would have been even stronger. This is a real counterweight that partially offsets the profit surge and could pressure future earnings if currency volatility continues.
It presents a genuine risk factor that tempers the positive profit news and could affect future profitability.

August 202628 Jul – 26 Aug 2026

▲3▼1

Glove Price Surge Drives Zhonghong Medical Profit Explosion

First-Half Profit Forecast Surges Over 23-Fold Zhonghong Medical expects first-half 2026 net profit of 140–210 million yuan, up 2,338%–3,557% year-on-year, driven by higher selling prices for health protection gloves and improved cost control. This signals a strong turnaround and boosts investor confidence, pushing the stock price up.
This is the core new event that directly explains the profit surge and its cause.
Actual First-Half Net Profit Jumps 26-Fold The semi-annual report confirmed net profit of 159 million yuan, up 2,662% year-on-year, with second-quarter profit alone at 154 million yuan. Revenue rose 19.46% to 1.478 billion yuan. This concrete result validates the earlier forecast and reinforces the positive price trend.
It provides the actual financial outcome, confirming the earlier forecast and strengthening the investment case.
Stock Price Rises Over 50% Since July As of August 25, the share price stood at 14.77 yuan, up more than 50% since July, with a market value of 6.3 billion yuan. This reflects the market's positive reaction to the profit surge and improving fundamentals.
It shows the market's cumulative response to the profit news, indicating sustained upward momentum.
Large Foreign Exchange Loss from Yuan-Dollar Swings The company incurred a large exchange loss due to fluctuations in the yuan against the US dollar. Excluding this, operating performance would have been even stronger. This is a real counterweight that partially offsets the profit surge and could pressure future earnings if currency volatility continues.
It presents a genuine risk factor that tempers the positive profit news and could affect future profitability.

Latest28 Jul – 26 Aug 2026

▲3▼1

Glove Price Surge Drives Zhonghong Medical Profit Explosion

First-Half Profit Forecast Surges Over 23-Fold Zhonghong Medical expects first-half 2026 net profit of 140–210 million yuan, up 2,338%–3,557% year-on-year, driven by higher selling prices for health protection gloves and improved cost control. This signals a strong turnaround and boosts investor confidence, pushing the stock price up.
This is the core new event that directly explains the profit surge and its cause.
Actual First-Half Net Profit Jumps 26-Fold The semi-annual report confirmed net profit of 159 million yuan, up 2,662% year-on-year, with second-quarter profit alone at 154 million yuan. Revenue rose 19.46% to 1.478 billion yuan. This concrete result validates the earlier forecast and reinforces the positive price trend.
It provides the actual financial outcome, confirming the earlier forecast and strengthening the investment case.
Stock Price Rises Over 50% Since July As of August 25, the share price stood at 14.77 yuan, up more than 50% since July, with a market value of 6.3 billion yuan. This reflects the market's positive reaction to the profit surge and improving fundamentals.
It shows the market's cumulative response to the profit news, indicating sustained upward momentum.
Large Foreign Exchange Loss from Yuan-Dollar Swings The company incurred a large exchange loss due to fluctuations in the yuan against the US dollar. Excluding this, operating performance would have been even stronger. This is a real counterweight that partially offsets the profit surge and could pressure future earnings if currency volatility continues.
It presents a genuine risk factor that tempers the positive profit news and could affect future profitability.